Copyright Reports & Markets. All rights reserved.

Encephalitis - Pipeline Review, H1 2019

Buy now

Table of Contents

    List of Tables

      List of Figures

        Introduction

          Global Markets Direct Report Coverage

            Encephalitis - Overview

              Encephalitis - Therapeutics Development

                Pipeline Overview

                  Pipeline by Companies

                    Products under Development by Companies

                      Encephalitis - Therapeutics Assessment

                        Assessment by Target

                          Assessment by Mechanism of Action

                            Assessment by Route of Administration

                              Assessment by Molecule Type

                                Encephalitis - Companies Involved in Therapeutics Development

                                  CEL-SCI Corp

                                    Knight Therapeutics Inc

                                      Sage Therapeutics Inc

                                        Encephalitis - Drug Profiles

                                          Amphotericin B sodium - Drug Profile

                                            Product Description

                                              Mechanism Of Action

                                                R&D Progress

                                                  CEL-1000 - Drug Profile

                                                    Product Description

                                                      Mechanism Of Action

                                                        R&D Progress

                                                          miltefosine - Drug Profile

                                                            Product Description

                                                              Mechanism Of Action

                                                                R&D Progress

                                                                  pneumococcal (13-valent) vaccine - Drug Profile

                                                                    Product Description

                                                                      Mechanism Of Action

                                                                        R&D Progress

                                                                          pneumococcal (23-valent) vaccine - Drug Profile

                                                                            Product Description

                                                                              Mechanism Of Action

                                                                                R&D Progress

                                                                                  Polyglactin 370 for Encephalitis - Drug Profile

                                                                                    Product Description

                                                                                      Mechanism Of Action

                                                                                        R&D Progress

                                                                                          SAGE-718 - Drug Profile

                                                                                            Product Description

                                                                                              Mechanism Of Action

                                                                                                R&D Progress

                                                                                                  Encephalitis - Dormant Projects

                                                                                                    Encephalitis - Product Development Milestones

                                                                                                      Featured News & Press Releases

                                                                                                        Jul 06, 2018: Knight receives adverse notice of reassessment from CRA

                                                                                                          Jun 28, 2017: FDA Grants Profounda Orphan Drug Designation for treatment of Granulomatous Amebic Encephalitis (GAE) with Miltefosine

                                                                                                            Dec 17, 2016: Profounda receives FDA orphan-drug designation for the Treatment of Primary Amebic Meningoencephalitis (PAM) with Miltefosine

                                                                                                              Aug 24, 2016: Orlando patient survives Primary Amebic Meningoencephalitis using Profoundas drug Impavido (miltefosine)

                                                                                                                Dec 15, 2015: U.S. Issues Patent on Corifungin

                                                                                                                  Feb 26, 2013: National Institutes of Health Supports Acea’s Research

                                                                                                                    Aug 22, 2011: Dr. James McKerrow, efficacy of Corifungin vs. Naegleria

                                                                                                                      Aug 22, 2011: FDA Grants 2nd Orphan drug designation

                                                                                                                        Feb 10, 2010: Dr. Jose Vazquez presents poster at ICAAC

                                                                                                                          Appendix

                                                                                                                            Methodology

                                                                                                                              Coverage

                                                                                                                                Secondary Research

                                                                                                                                  Primary Research

                                                                                                                                    Expert Panel Validation

                                                                                                                                      Contact Us

                                                                                                                                        Disclaimer

                                                                                                                                        Encephalitis - Pipeline Review, H1 2019

                                                                                                                                        Summary

                                                                                                                                        Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalitis - Pipeline Review, H1 2019, provides an overview of the Encephalitis (Central Nervous System) pipeline landscape.

                                                                                                                                        Encephalitis is an inflammation of the brain tissue. There are two main types of encephalitis: primary and secondary. Primary encephalitis occurs when a virus directly infects the brain and spinal cord. Secondary encephalitis occurs when an infection starts elsewhere in the body and then travels to brain. Causes include common viruses, childhood viruses, and arboviruses. Risk factors include age and weak immune systems. Symptoms include fever, headache, vomiting, stiff neck, coma and hallucinations. Treatment includes pain killers, corticosteroids, anticonvulsants and sedatives.

                                                                                                                                        Report Highlights

                                                                                                                                        Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Encephalitis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Encephalitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

                                                                                                                                        The Encephalitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 1 and 6 respectively.

                                                                                                                                        Encephalitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

                                                                                                                                        Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

                                                                                                                                        Scope

                                                                                                                                        - The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalitis (Central Nervous System).
                                                                                                                                        - The pipeline guide reviews pipeline therapeutics for Encephalitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
                                                                                                                                        - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
                                                                                                                                        - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
                                                                                                                                        - The pipeline guide reviews key companies involved in Encephalitis (Central Nervous System) therapeutics and enlists all their major and minor projects.
                                                                                                                                        - The pipeline guide evaluates Encephalitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
                                                                                                                                        - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
                                                                                                                                        - The pipeline guide reviews latest news related to pipeline therapeutics for Encephalitis (Central Nervous System)

                                                                                                                                        Reasons to buy

                                                                                                                                        - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
                                                                                                                                        - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
                                                                                                                                        - Find and recognize significant and varied types of therapeutics under development for Encephalitis (Central Nervous System).
                                                                                                                                        - Classify potential new clients or partners in the target demographic.
                                                                                                                                        - Develop tactical initiatives by understanding the focus areas of leading companies.
                                                                                                                                        - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
                                                                                                                                        - Formulate corrective measures for pipeline projects by understanding Encephalitis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
                                                                                                                                        - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
                                                                                                                                        - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

                                                                                                                                        Buy now